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EPIDEMIOLOGY
Stable and Low Prevalence of Transmitted HIV
Type 1 Drug Resistance Despite Two Decades
of Antiretroviral Therapy in Hong Kong
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Abstract
Transmitted HIV resistance is of both clinical and public health importance. Baseline genotypic resistance testing
was performed for HIV-1-infected treatment-naive patients who were newly diagnosed between 2003 and 2007
and attended the government HIV clinic in Hong Kong. International AIDS Society–USA mutation figures and
the Stanford resistance interpretation algorithm were used to identify resistance mutations and drug suscepti-
bility, respectively. The pattern and factors associated with resistance were examined. The presence of one or
more IAS–USA resistance mutations was found in 26 (3.6%) of 731 patients over the 5-year study period. Overall,
protease inhibitor (PI) resistance mutations were most common (16), followed by nucleoside reverse tran-
scriptase inhibitors (NRTIs) (8) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) (3). Resistance to
drugs in one, two, and three classes was present in 25 (3.4%), 1 (0.1%), and 0, respectively. Seventy-eight (10.7%)
had strains of reduced susceptibility, as predicted by the Stanford algorithm to display at least low-level
resistance to one or more drugs of the three classes. Intermediate or high-level resistance was found in 1.6%
overall, and in descending order for NRTIs, PIs, and NNRTIs. There was no temporal trend of increase in
resistance. Sex between men, Chinese ethnicity, and lower baseline CD4 were associated with harboring resistant
strains as elucidated by either method. We conclude that transmitted HIV-1 drug resistance is uncommon in up
to two decades of antiretroviral therapy in Hong Kong. The situation has to be continually monitored for any
change in significance.
Introduction
The advent of highly active antiretroviral therapy(HAART) has turned HIV disease into a chronic medical
condition with greatly reduced AIDS-related morbidity and
mortality.1–3 Nevertheless, HAART is not a panacea, for de-
spite treatment, HIV-infected patients still have a shorter life
expectancy than people in the general population.4 Moreover,
as with other antiinfectives, resistance may have existed be-
fore HAART is started or may emerge during the course of
treatment. Drug resistance is one major factor contributing to
HIV treatment failure.5 It is hence prudent to tackle the re-
sistance issue if we are to achieve optimal HIV management
and care.
Resistance testing is now a standard component of labo-
ratory diagnosis and monitoring of HIV infection.6 Together
with CD4 and HIV-1 viral load measurements, these three
specific tools greatly aid day-to-day medical management of
HIV/AIDS patients. As early as 2000, the International AIDS
Society (IAS)–USA recommended using the HIV resistance
test in patients with chronic HIV infection before initiation of
antiretroviral therapy.7 The rationale is that baseline resis-
tance may reduce treatment efficacy, thus requiring the first-
line regimen to be adjusted accordingly. Resistance sampling
should be done as close to the time of infection as possible, as
resistant viruses back-mutate to wild-type genotypes with
time. Genotypic resistance testing (GRT) is often the preferred
test to phenotypic assay because of its simpler laboratory
procedures and stronger evidence of virologic benefits and
cost effectiveness.8
The usefulness of application of resistance testing in treat-
ment-naive subjects may, however, differ from place to place
due to the varied epidemiology of transmitted resistance. The
HIV clinic at the Integrated Treatment Centre (ITC) of the
Hong Kong Department of Health has introduced GRT in the
baseline workup of newly diagnosed patients since 2003. We
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set out to examine the prevalence of transmitted resistance, its
temporal trend, and associated factors in a cohort of new
patients seen over a period of 5 years.
Materials and Methods
Study subjects
The ITC is the largest care provider to adults living with
HIV in Hong Kong. Our patients are referred from a variety of
sources, including hospitals, sexually transmitted infections
clinics, and voluntary HIV testing sites. Preceded by mono-
therapy with the first use of zidovudine in 1987 and afterward
by dual therapy, HAART became the standard antiretroviral
treatment in late 1996.9 About 85% of patients with AIDS
and/or CD4<200 cells/ml were on HAART.10 Treatment and
prophylaxis of opportunistic infections were prescribed as
appropriate per international recommendations. The AIDS
case definition for adults and adolescents in Hong Kong is
adopted from the US CDC 1993 definition, with the following
modifications: (1) disseminated penicilliosis is included as an
AIDS-defining illness (ADI), (2) pulmonary or cervical lymph
node tuberculosis is counted as an ADI only if the CD4 count
is <200 cells/ml, and (3) a CD4 count of <200 cells/ml alone is
not considered as AIDS.11 In the present study, we analyzed
patients who were diagnosed as HIV-1 positive between
2003 and 2007 and had been antiretroviral naive before a
baseline genotypic resistance test was done at our clinic. The
testing forms a surveillance effort to monitor HIV resistance
in the locality. We looked at all patients, including those
with recent infections as defined by a prior negative HIV
antibody test or seroconversion illness within 1 year of HIV
diagnosis.
Resistance test and interpretation
The genotypic assay is the resistance test employed in our
clinic. The laboratory procedures of HIV-1 RNA extraction,
amplification, and sequencing have been previously de-
scribed.12 In addition to an FDA-approved ViroSeqTM system,
an in-house system was also used. We had demonstrated
comparable performance in terms of sensitivity, specificity,
and detection of resistance mutations on a wide range of HIV-
1 subtypes for this in-house genotyping system.13 Two
methods were used to examine the harboring of resistant
strains in our study patients. First, we assessed the presence of
resistance mutations (RTI resistance associated or major PI
resistance associated) against the Mutations Figures pub-
lished by the IAS-USA Drug Mutations Group (December
2008 update, http://iasusa.org). Second, the pol sequences
were analyzed using the Stanford University HIV Drug Re-
sistance Database HIVdb program (version 4.2.6 http://
hivdb.stanford.edu). Under the Stanford algorithm, there are
five interpretation results of susceptibility to each drug,
namely susceptible, potential low-level resistance, low-level
resistance, intermediate resistance, and high-level resistance.
In this study, HIV-1 strains predicted to exhibit low-level or
greater resistance per Stanford interpretation were counted as
having reduced drug susceptibility and thus resistance. We
restricted data analysis to the three mainstay drug classes—
nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), and
protease inhibitors (PIs), as the newer classes, e.g., fusion in-
hibitor and integrase inhibitor, had not been used by our clinic
through the study period.
Statistical analysis
Differences in categorical items such as proportion of re-
sistant strains were examined by logistic regression tests
while continuous variables were analyzed by independent t
test. Cox proportional hazards logistic regression of univari-
ate and multivariate analyses was used to study demographic
and HIV infection variables that may be associated with re-
sistance. Their crude and adjusted hazard ratios and 95%
confidence intervals were calculated. We used SPSS (version
11.0) for all statistical analyses. All tests of significance were
two-sided, and a p< 0.05 was considered to be statistically
significant.
Results
During the 5-year study period, a total of 865 antiretroviral-
naive patients with newly diagnosed HIV infection attended
our clinic. Of them, 134 (15.5%) were excluded from analysis
because of the lack of baseline genotypic resistance testing
results. Table 1 shows the patient and HIV disease charac-
teristics of the 731 study subjects. The majority of the patients
were male (87%), aged between 30 and 49 years (58%), and
had acquired HIV via sexual contact (86.6%). HIV-1 subtype B
and CRF01_AE accounted for 42.4% and 43.1%, respectively.
Cases of recent infection significantly differed from nonrecent
cases in being younger, more often infected with the B sub-
type, and less likely to be AIDS patients, and having a higher
baseline CD4 cell count. There were more men who have sex
with men (MSM) among recently infected patients, but not
with statistical significance. There was no significant change
in disease stage of the patients in terms of presenting CD4 or
AIDS over the study period.
Table 2 shows the resistance profile of the study subjects.
Overall, 26 (3.6%) had at least one resistance mutations per
IAS–USA figures. Each year, one to eight patients (0.8–6.4%)
were detected as having baseline resistance mutations.
Among all patients harboring resistant viruses, PI resistance
was the commonest and was present in 16 subjects, with
M46L (seven), M46I (three), and L33F (three) being the most
frequent mutations. NRTI came second in class with eight
patients showing resistance; thymidine analogue mutations
(eight) were much commoner than M184V (one). Baseline
NNRTI resistance was present in only three (0.4%) subjects.
Taken together, resistance to one and two classes of antivirals
was found in 25(3.4%) and 1(0.1%). None of the patients had
three-class resistance.
Based on the Stanford HIVdb algorithm, drug susceptibil-
ity was possibly reduced in 78 (10.7%) of subjects over the 5-
year period (Fig. 1). Most of the reduced drug susceptibility
cases were of low-level resistance and only 12 (1.6%) were
intermediate or high-level resistance. The frequency of resis-
tance by class per Stanford analysis is different from that
based on IAS–USA mutation figures. Considering all cases
with reduced drug susceptibility, resistance to NNRTI was
most common and was found in 37 (5.1%), followed by 24
(3.3%) with NRTI resistance and 22 (3.0%) with PI resistance.
If only strains with intermediate or high-level resistance were
considered, the NRTI class ranked first at six (0.8%) and the
NNRTI class came last at two (0.3%). Three (0.4%) patients
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harbored viruses that had reduced susceptibility to two clas-
ses of drugs, but only of low-level resistance with none being
intermediate or high-level resistant.
Five patients with IAS–USA mutations did not have re-
duced susceptibility by Stanford while 57 subjects with re-
duced susceptibility did not show IAS–USA mutations. The
commonest mutations of these patients leading to reduced
susceptibility were for the reverse transcriptase gene: V179D
(22), T69N (10), A98G (5), V179E (4), and for the protease gene:
V82I (4), G16E (3), K20I (2), L10I (2), and T74S (2). Many of
them are minor mutations. We examined treatment response
among patients with CD4 <200 cells/ml and found that 100%
(1/1), 100% (8/8), and 90.3% (28/31) of subjects with IAS–
USA mutations alone, both IAS–USA mutations and reduced
susceptibility, and reduced susceptibility alone, respectively,
had undetectable viral load at 12 months post-HAART.
We performed factor analysis of resistant cases as identified
from both the IAS–USA and Stanford methods. Univariate
and multivariate analyses using Cox proportional hazards
regression showed that sex between men as the exposure
category was associated with a higher likelihood of the
presence of IAS–USA mutations (Table 3). Recent infection,
age, gender, ethnicity, HIV-1 subtype, baseline CD4, and viral
load were not significant factors. Also, year of HIV diagnosis
was not an associated variable and there was no definite time
trend of resistance. Interestingly, non-Chinese and baseline
CD4 200 cells/ml were associated with a lower risk of re-
duced drug susceptibility by the Stanford algorithm on both
univariate and multivariate analyses (Table 4). Nonsexual
HIV exposure was a factor in univariate but not multivariate
analysis. Again, year of HIV diagnosis was not a significant
variable. There was no temporal pattern in reduced suscep-
tibility to any drugs by the Stanford algorithm during the
study period (Fig. 1). Moreover, none of the factors examined
was significant if we excluded low-level resistance cases and
analyzed only cases of intermediate or high-level resistance.
Table 1. Demographic and baseline HIV disease characteristics
All Recent infection (<1 year) Chronic infection p Value
Number of patients 731 114 (15.6%) 617 (84.4%)
Sex, n (%) 0.395
Male 636 (87.0) 102 (89.7) 534 (86.6)
Female 95 (13.0) 12 (10.5) 83 (13.5)
Ethnicity, n (%) 0.262
Chinese 560 (76.6) 92 (80.7) 468 (75.9)
Non-Chinese 171 (23.4) 22 (19.3) 149 (24.2)
Age, year 0.023
Mean 39.1 36.6 39.5
Median 36.3 34.7 36.9
HIV exposure category, n (%) 0.908
Heterosexual 311 (42.5) 37 (32.5) 274 (44.4)
Sex between men 322 (44.1) 74 (64.9) 248 (40.2)
Other 98 (13.4) 3 (2.6) 95 (15.4)
HIV-1 subtype, n (%) <0.001
B 310 (42.4) 70 (61.4) 240 (38.9)
CRF01_AE 315 (43.1) 34 (29.8) 281 (45.5)
Other 82 (11.2) 5 (4.4) 77 (12.5)
AIDS, n (%) 155 (21.2) 1 (0.9) 154 (25.0) <0.001
CD4 in cells/ml, median (range) 247 (0–1423) 405.5 (20–942) 208 (0–1423) <0.001
Viral load in log copies/ml, mean (range) 4.95 (2.6–6.86) 4.91 (2.6–6.34) 4.97 (2.6–6.86) 0.029
Table 2. Resistance Profile by Presence of Major
Mutation per IAS-USA Mutation Figures (2003–2007)
Mutation
Frequency
in all patients,
n (%)
Frequency in patients
with drug-resistant
strains, %
All drugs
Any (NRTI,
NNRTI, PI)
26 (3.6)
1-class 25 (3.4) 96.2
2-class 1 (0.1) 3.9
3-class 0 (0.0) 0.0
NRTI
Any 8 (1.1) 30.8
1 6 (0.8) 23.1
2 2 (0.3) 7.7
M41L 2 (0.3) 7.7
D67N 2 (0.3) 7.7
M184V 1 (0.1) 3.9
M184I 1 (0.1) 3.9
K219Q 4 (0.5) 15.4
NNRTI
Any 3 (0.4) 11.5
1 3 (0.4) 11.5
2 0 (0.0) 0.0
K103N 1 (0.1) 3.8
V108I 1 (0.1) 3.8
Y181C 1 (0.1) 3.8
PI
Any 16 (2.2) 61.5
1 15 (2.1) 57.7
2 1 (0.1) 3.9
L33F 3 (0.4) 11.5
M46I 3 (0.4) 11.5
M46L 7 (1.0) 26.9
Q58E 2 (0.3) 7.7
V82A 1 (0.1) 3.9
L90M 1 (0.1) 3.9
STABLY LOW TRANSMITTED HIV RESISTANCE IN HAART ERA 1081
Discussion
In this study, we examined the prevalence and factors of
transmitted HIV-1 drug resistance in Hong Kong, two de-
cades into the availability of the first antiretroviral drug zi-
dovudine in 1987 and 6–10 years after full application of
HAART as the local standard in 1997. Being the largest HIV
clinic in Hong Kong, our findings can shed light on the
territory-wide situation. Indeed, our study population was
similar in basic demographics and HIV disease characteris-
tics to all reported infections in Hong Kong during the pe-
riod, except that there was a smaller proportion of female
and non-Chinese patients (data not shown). Published
studies on HIV resistance were mostly from Western de-
veloped countries in the past. However, reports are now
increasingly being made in other parts of the world, in-
cluding Asia.14–17 Our study population, comprising mostly
Chinese, contributes to the understanding of resistance in
the Asia Pacific region. Also, unlike some previous Asian
reports with limited treatment accessibility,14,16 our findings
can provide information concerning transmitted resistance
against a background of high treatment coverage beyond
Western countries.
We found a low frequency of drug resistance at about 3% in
treatment-naive patients over the 5-year study period, and
without a discernible rising trend over time by two methods
of resistance determination. Furthermore, most of these pa-
tients harbored strains resistant to one drug class only, as
dual-class resistance was rare at <0.2% and three-class resis-
tance was nonexistent. The frequency of transmitted resis-
tance ranged from 5% to 10% in North America and European
countries18–20 but had been reported to be as high as 20–
25%.21 Data from 1996 to 2005 of the Swiss HIV cohort sug-
gested that transmission of drug resistance in the setting of
easy access to antiretroviral treatment can remain stable and
be kept at a low level.18 We believe that good drug adherence
contributed to the low resistance found in this study, as we
previously reported <4% of our patients had less than 95%
adherence.22 Improved treatment efficacy with more patients
in virologic success, which reduces the likelihood of trans-
mission of resistant strains, has also been postulated to con-
tribute to the stable or decreasing transmitted resistance in
Western Europe.19,23 Noteworthy, our study population did
not have an increase in NNRTI-resistant virus transmission
over time, in contrast to several overseas reports.18–20,24,25 This
is most encouraging as single resistance mutation can effec-
tively render the whole class of NNRTIs useless, with the
possible exception of etravirine.
The importance of assessing and monitoring for transmit-
ted HIV-1 drug resistance cannot be overstated, as transmis-
sion of drug-resistant HIV-1 has been reported in many
countries with access to antiretroviral treatment, albeit at
different levels. The World Health Organisation (WHO) re-
commended that the capability of resistance testing be de-
veloped even in resource-constrained settings, using a
threshold survey of recently infected individuals as a mini-
mum-resource strategy to evaluate transmitted resistance.26
Such a recommendation should be adopted or taken note of
by all places instituting antiretroviral therapy, which is
quickly becoming the standard due to the global scale up of
treatment. The value of monitoring transmitted resistance is
to guide and maximize the success of first-line treatment
regimens designed under a public health approach as advo-
cated by the WHO. The prevalence of transmitted resistance is
set at thresholds of 5% and 15%, representing low and high
levels of resistance, respectively.
FIG. 1. Proportion of patients with predicted reduced drug susceptibility by Stanford HIVdb algorithm (2003–2007).
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In the absence of a universal consensus on the interpreta-
tion of genotypic resistance results, the frequency of trans-
mitted resistance would depend on the definition and method
employed in a particular study to gauge HIV-1 drug resis-
tance.27 We found that transmitted PI resistance presented
more frequently than NRTI resistance in our patient popula-
tion per the presence of IAS–USA mutations. Even though one
study supported this finding,28 other reports had shown the
reverse, that NRTI resistance was the most frequently
found.29,30 Our clinic has consistently used PI as the preferred
(>70%) regimen for treatment initiation. In fact, M46I/L
mutations, which confer resistance to indinavir, accounted for
half of the cases with PI resistance. Such findings could be
related to our frequent use of indinavir, which is well known
to cause intolerance, in the early days of the HAART era.
Therefore, the uncommon use of NNRTIs in the first regimen
contributed to the relative rarity of significant NNRTI muta-
tions. Nonetheless, due to methodological variation in data
interpretation, it is not appropriate to directly compare our
prevalence findings with those collected in other studies. It is
interesting but prospective that the resistance results differed
between mutation figures and the drug susceptibility algo-
rithm in our study. However, the frequency of resistance as
informed by the Stanford algorithm was similar to consensus
mutation findings, if only intermediate or above level of re-
duced susceptibility was considered. Indeed, our clinic ex-
perience showed that treatment efficacy was seldom
compromised in patients with just low-level resistance by the
Stanford analysis, supporting the greater clinical relevance of
using an intermediate or higher level of reduced susceptibil-
ity. We suggest taking reference of both IAS–USA mutation
figures and the Stanford algorithm testing for guiding treat-
ment as they are widely used methods of genotypic resistance
interpretation.
Factor analysis also yielded different findings of resistance
association for IAS–USA mutation figures and drug suscep-
tibility testing by Stanford. On multivariate analysis, while
HIV exposure category is a risk factor by mutation figures,
Chinese ethnicity and lower baseline CD4 were associated
with transmitted resistance by the Stanford algorithm. The
fact that resistant cases were few could have limited the
analysis of factors associated with the occurrence of resis-
tance, particularly when only intermediate or above level re-
sistance was considered. Our findings did not suggest an
increasing trend of transmitted resistance overall or a higher
prevalence in recent infections; the true extent of the latter
Table 3. Univariate and Multivariate Analyses of Factors Associated with the Presence
of Resistance Mutation to Any Drug Class (2003–2007)
Variable n Crude HR (95% CI) Adjusted HR (95% CI)
Age, year
<40 16 1
40 10 1.25 (0.57–2.78)
Sex
Male 24 1
female 2 0.68 (0.16–2.89)
Ethnicity
Chinese 23 1
Non-Chinese 3 0.26 (0.08–0.88)
HIV exposure category
Heterosexual 7 1 1
Sex between men 18 3.04 (1.25–7.37) 3.04 (1.25–7.37)
Other 1 0.29 (0.04–2.39) 0.29 (0.04–2.39)
HIV-1 subtype, n (%)
B 15 1
CRF01_AE 10 0.48 (0.21–1.09)
Other 1 0.21 (0.03–1.56)
AIDS
Yes 3 1
No 23 2.63 (0.79–8.76)
Baseline CD4 in cells/ml
<200 11 1
200 15 1.07 (0.49–2.33)
Baseline viral load in copies/ml
<5 log 17 1
5 log 9 0.57 (0.25–1.27)
Recent infection
No 21 1
Yes 5 1.50 (0.57–3.99)
Year of HIV diagnosis
2003 6 1
2004 1 0.15 (0.18–1.27)
2005 6 0.86 (0.28–2.66)
2006 8 0.84 (0.29–2.45)
2007 5 0.47 (0.14–1.55)
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might have been missed in some patients without a previous
HIV test or seroconversion illness. In all, the low frequency of
transmitted resistance and the few associated factors identi-
fied make selective identification of at-risk patients for pre-
treatment resistance testing impossible. To improve patient
management and the yield of surveillance, our findings sup-
port testing of all clinic patients. Whether resistance is per-
sistently higher in certain subgroups requires further
monitoring and studies.
Our study had several limitations. We could have over-
estimated the transmitted resistance if some resistant patients
had actually received treatment before and then developed
resistance. But this was unlikely as all subjects were our clinic
patients and we had their detailed history, unlike that of a
pure laboratory setting, which may not have sufficient clinical
information on the cases. On the other hand, some resistant
cases could have their viruses reverted to wild types at the
time of HIV diagnosis after long-standing infection. Under-
estimation due to this factor is, however, unavoidable unless
only acute or recent infections are studied. Also, its effect, if
any, would likely be similar throughout the study period as
there was no evidence of increasing late presentations as re-
flected by the presenting CD4 or AIDS diagnosis. Consistent
sampling for baseline GRT of newly diagnosed patients at our
clinic is a strength of our findings.
In summary, the present study suggests a stable and low
level of transmitted drug resistance in HIV-infected patients
attending the government HIV clinic despite two decades of
antiretroviral treatment provision in Hong Kong. Although
this observation for the moment is reassuring, transmitted
HIV resistance has to be continually monitored to inform
public health epidemiology as well as drug treatment at an
individual care level.
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Table 4. Univariate and Multivariate Analyses of Factors Associated with Reduced Susceptibility
to Any Drug Class (Low or Above the Level of Resistance) by the Stanford Algorithm (2003–2007)
Variable n Crude HR (95% CI) Adjusted HR (95% CI)
Age, year
<40 46 1
40 32 1.48 (0.93–2.34)
Sex
Male 69
female 9 1.05 (0.53–2.12)
Ethnicity
Chinese 64 1 1
Non-Chinese 14 0.37 (0.20–0.68) 0.53 (0.28–0.99)
HIV exposure category
Heterosexual 37 1
Sex between men 35 1.27 (0.79–2.05)
Other 6 0.32 (0.13–0.75)
HIV-1 subtype, n (%)
B 33 1
CRF01_AE 35 0.63 (0.38–1.04)
Other 8 0.67 (0.31–1.46)
AIDS
Yes 21 1
No 57 0.98 (0.58–1.63)
CD4 in cells/ml
<200 47 1 1
200 31 0.55 (0.35–0.86) 0.55 (0.35–0.89)
Viral load in copies/ml
<5 log 37 1
5 log 41 1.13 (0.72–1.77)
Recent infection
No 71 1
Yes 7 0.66 (0.30–1.43)
Year of HIV diagnosis
2003 16 1
2004 15 0.94 (0.46–1.93)
2005 12 0.71 (0.33–1.53)
2006 21 0.97 (0.49–1.9)
2007 14 0.58 (0.28–1.22)
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